Unrelated donor marrow transplantation for chronic myelogenous leukaemia

G. Dini, T. Lamparelli, R. Rondelli, R. Lanino, M. Barbanti, C. Costa, L. Manfredini, S. Guidi, G. Rosti, E. P. Alessandrino, F. Locatelli, P. Marenco, D. Soligo, P. Di Bartolomeo, F. Aversa, G. La Nasa, A. Busca, I. Majolino, A. De Laurenzi, A. Bacigalupo

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Between January 1989 and July 1995 the search for an unrelated donor (UD) was started for 379 consecutive Italian patients with Philadelphia positive (Ph+) chronic myelogenous leukaemia (CML). 89 (23%) were transplanted. The overall probability of transplant before and after December 1991 was 16% and 49% respectively (P= 0.0001), and average interval between search activation and graft was 23 months and 13 months, respectively (P=O.0001). Disease-free survival (DFS) following 60 consecutive transplants performed before February 1996 was 41.5% at 48 months and was 64% for patients grafted after January 1993. In univariate analysis, five variables had a favourable effect on DFS: year of bone marrow transplantation (BMT) after 1993 (P=0.0002), HLA-DRB1 donor/recipient (D/R) match (P= 0.0006), total body irradiation (TBI) containing regimen (P=0.0006), graft-versus- host disease (GvHD) prophylaxis including 'early' cyclosporin before the transplant, and a marrow cell dose > 3 x 108/kg of recipient body weight (P=0.04). Multivariate analysis confirmed that HLA identity (P=0.006), TBI- containing regimen (P= 0.0001) and 'early cyclosporin' (P=0.04) were associated with higher DFS. Transplant-related mortality (TRM) was 67% in patients grafted before January 1993 and 30% in patients grafted subsequently (P = 0.002). Multivariate analysis confirmed DRB1 identity (P=0.03) and TBI- containing regimen (P = 0.0005) to be independent factors predictive of low TRM. This suggests that the outcome of patients transplanted from an HLA DRB1 matched donor, after a TBI-containing preparative regimen, is similar to results recently reported in patients transplanted from geno-identical siblings. These results indicate that the search should be initiated at diagnosis for patients <45 years of age and UD BMT should be considered early in the disease course for those with an available DRB1-matched unrelated donor.

Original languageEnglish
Pages (from-to)544-552
Number of pages9
JournalBritish Journal of Haematology
Volume102
Issue number2
DOIs
Publication statusPublished - 1998

Fingerprint

Unrelated Donors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transplantation
Bone Marrow
Whole-Body Irradiation
Transplants
Disease-Free Survival
HLA-DRB1 Chains
Bone Marrow Transplantation
Cyclosporine
Multivariate Analysis
Mortality
Graft vs Host Disease
Siblings
Body Weight
Tissue Donors

Keywords

  • Bone marrow transplantation
  • CML
  • Marrow donor registries
  • Unrelated BMT

ASJC Scopus subject areas

  • Hematology

Cite this

Unrelated donor marrow transplantation for chronic myelogenous leukaemia. / Dini, G.; Lamparelli, T.; Rondelli, R.; Lanino, R.; Barbanti, M.; Costa, C.; Manfredini, L.; Guidi, S.; Rosti, G.; Alessandrino, E. P.; Locatelli, F.; Marenco, P.; Soligo, D.; Di Bartolomeo, P.; Aversa, F.; La Nasa, G.; Busca, A.; Majolino, I.; De Laurenzi, A.; Bacigalupo, A.

In: British Journal of Haematology, Vol. 102, No. 2, 1998, p. 544-552.

Research output: Contribution to journalArticle

Dini, G, Lamparelli, T, Rondelli, R, Lanino, R, Barbanti, M, Costa, C, Manfredini, L, Guidi, S, Rosti, G, Alessandrino, EP, Locatelli, F, Marenco, P, Soligo, D, Di Bartolomeo, P, Aversa, F, La Nasa, G, Busca, A, Majolino, I, De Laurenzi, A & Bacigalupo, A 1998, 'Unrelated donor marrow transplantation for chronic myelogenous leukaemia', British Journal of Haematology, vol. 102, no. 2, pp. 544-552. https://doi.org/10.1046/j.1365-2141.1998.00790.x
Dini, G. ; Lamparelli, T. ; Rondelli, R. ; Lanino, R. ; Barbanti, M. ; Costa, C. ; Manfredini, L. ; Guidi, S. ; Rosti, G. ; Alessandrino, E. P. ; Locatelli, F. ; Marenco, P. ; Soligo, D. ; Di Bartolomeo, P. ; Aversa, F. ; La Nasa, G. ; Busca, A. ; Majolino, I. ; De Laurenzi, A. ; Bacigalupo, A. / Unrelated donor marrow transplantation for chronic myelogenous leukaemia. In: British Journal of Haematology. 1998 ; Vol. 102, No. 2. pp. 544-552.
@article{a3dc985c66ea4249a0244f8a34f8e3bc,
title = "Unrelated donor marrow transplantation for chronic myelogenous leukaemia",
abstract = "Between January 1989 and July 1995 the search for an unrelated donor (UD) was started for 379 consecutive Italian patients with Philadelphia positive (Ph+) chronic myelogenous leukaemia (CML). 89 (23{\%}) were transplanted. The overall probability of transplant before and after December 1991 was 16{\%} and 49{\%} respectively (P= 0.0001), and average interval between search activation and graft was 23 months and 13 months, respectively (P=O.0001). Disease-free survival (DFS) following 60 consecutive transplants performed before February 1996 was 41.5{\%} at 48 months and was 64{\%} for patients grafted after January 1993. In univariate analysis, five variables had a favourable effect on DFS: year of bone marrow transplantation (BMT) after 1993 (P=0.0002), HLA-DRB1 donor/recipient (D/R) match (P= 0.0006), total body irradiation (TBI) containing regimen (P=0.0006), graft-versus- host disease (GvHD) prophylaxis including 'early' cyclosporin before the transplant, and a marrow cell dose > 3 x 108/kg of recipient body weight (P=0.04). Multivariate analysis confirmed that HLA identity (P=0.006), TBI- containing regimen (P= 0.0001) and 'early cyclosporin' (P=0.04) were associated with higher DFS. Transplant-related mortality (TRM) was 67{\%} in patients grafted before January 1993 and 30{\%} in patients grafted subsequently (P = 0.002). Multivariate analysis confirmed DRB1 identity (P=0.03) and TBI- containing regimen (P = 0.0005) to be independent factors predictive of low TRM. This suggests that the outcome of patients transplanted from an HLA DRB1 matched donor, after a TBI-containing preparative regimen, is similar to results recently reported in patients transplanted from geno-identical siblings. These results indicate that the search should be initiated at diagnosis for patients <45 years of age and UD BMT should be considered early in the disease course for those with an available DRB1-matched unrelated donor.",
keywords = "Bone marrow transplantation, CML, Marrow donor registries, Unrelated BMT",
author = "G. Dini and T. Lamparelli and R. Rondelli and R. Lanino and M. Barbanti and C. Costa and L. Manfredini and S. Guidi and G. Rosti and Alessandrino, {E. P.} and F. Locatelli and P. Marenco and D. Soligo and {Di Bartolomeo}, P. and F. Aversa and {La Nasa}, G. and A. Busca and I. Majolino and {De Laurenzi}, A. and A. Bacigalupo",
year = "1998",
doi = "10.1046/j.1365-2141.1998.00790.x",
language = "English",
volume = "102",
pages = "544--552",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - Unrelated donor marrow transplantation for chronic myelogenous leukaemia

AU - Dini, G.

AU - Lamparelli, T.

AU - Rondelli, R.

AU - Lanino, R.

AU - Barbanti, M.

AU - Costa, C.

AU - Manfredini, L.

AU - Guidi, S.

AU - Rosti, G.

AU - Alessandrino, E. P.

AU - Locatelli, F.

AU - Marenco, P.

AU - Soligo, D.

AU - Di Bartolomeo, P.

AU - Aversa, F.

AU - La Nasa, G.

AU - Busca, A.

AU - Majolino, I.

AU - De Laurenzi, A.

AU - Bacigalupo, A.

PY - 1998

Y1 - 1998

N2 - Between January 1989 and July 1995 the search for an unrelated donor (UD) was started for 379 consecutive Italian patients with Philadelphia positive (Ph+) chronic myelogenous leukaemia (CML). 89 (23%) were transplanted. The overall probability of transplant before and after December 1991 was 16% and 49% respectively (P= 0.0001), and average interval between search activation and graft was 23 months and 13 months, respectively (P=O.0001). Disease-free survival (DFS) following 60 consecutive transplants performed before February 1996 was 41.5% at 48 months and was 64% for patients grafted after January 1993. In univariate analysis, five variables had a favourable effect on DFS: year of bone marrow transplantation (BMT) after 1993 (P=0.0002), HLA-DRB1 donor/recipient (D/R) match (P= 0.0006), total body irradiation (TBI) containing regimen (P=0.0006), graft-versus- host disease (GvHD) prophylaxis including 'early' cyclosporin before the transplant, and a marrow cell dose > 3 x 108/kg of recipient body weight (P=0.04). Multivariate analysis confirmed that HLA identity (P=0.006), TBI- containing regimen (P= 0.0001) and 'early cyclosporin' (P=0.04) were associated with higher DFS. Transplant-related mortality (TRM) was 67% in patients grafted before January 1993 and 30% in patients grafted subsequently (P = 0.002). Multivariate analysis confirmed DRB1 identity (P=0.03) and TBI- containing regimen (P = 0.0005) to be independent factors predictive of low TRM. This suggests that the outcome of patients transplanted from an HLA DRB1 matched donor, after a TBI-containing preparative regimen, is similar to results recently reported in patients transplanted from geno-identical siblings. These results indicate that the search should be initiated at diagnosis for patients <45 years of age and UD BMT should be considered early in the disease course for those with an available DRB1-matched unrelated donor.

AB - Between January 1989 and July 1995 the search for an unrelated donor (UD) was started for 379 consecutive Italian patients with Philadelphia positive (Ph+) chronic myelogenous leukaemia (CML). 89 (23%) were transplanted. The overall probability of transplant before and after December 1991 was 16% and 49% respectively (P= 0.0001), and average interval between search activation and graft was 23 months and 13 months, respectively (P=O.0001). Disease-free survival (DFS) following 60 consecutive transplants performed before February 1996 was 41.5% at 48 months and was 64% for patients grafted after January 1993. In univariate analysis, five variables had a favourable effect on DFS: year of bone marrow transplantation (BMT) after 1993 (P=0.0002), HLA-DRB1 donor/recipient (D/R) match (P= 0.0006), total body irradiation (TBI) containing regimen (P=0.0006), graft-versus- host disease (GvHD) prophylaxis including 'early' cyclosporin before the transplant, and a marrow cell dose > 3 x 108/kg of recipient body weight (P=0.04). Multivariate analysis confirmed that HLA identity (P=0.006), TBI- containing regimen (P= 0.0001) and 'early cyclosporin' (P=0.04) were associated with higher DFS. Transplant-related mortality (TRM) was 67% in patients grafted before January 1993 and 30% in patients grafted subsequently (P = 0.002). Multivariate analysis confirmed DRB1 identity (P=0.03) and TBI- containing regimen (P = 0.0005) to be independent factors predictive of low TRM. This suggests that the outcome of patients transplanted from an HLA DRB1 matched donor, after a TBI-containing preparative regimen, is similar to results recently reported in patients transplanted from geno-identical siblings. These results indicate that the search should be initiated at diagnosis for patients <45 years of age and UD BMT should be considered early in the disease course for those with an available DRB1-matched unrelated donor.

KW - Bone marrow transplantation

KW - CML

KW - Marrow donor registries

KW - Unrelated BMT

UR - http://www.scopus.com/inward/record.url?scp=7344266888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7344266888&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1998.00790.x

DO - 10.1046/j.1365-2141.1998.00790.x

M3 - Article

VL - 102

SP - 544

EP - 552

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -